Form 8.3 - [Abbvie. Inc]
April 06 2020 - 12:19PM
Dow Jones News
TIDM0QCV TIDM0Y7T
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING
1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) State Street Global Advisors &
Affiliates
--------------------------------------------- -------------------------------
Company dealt in AbbVie Inc.
--------------------------------------------- -------------------------------
Class of relevant security to which US$0.01 common stock
the dealings being disclosed relate (Note 2)
--------------------------------------------- -------------------------------
Date of dealing 03(rd) April 2020
--------------------------------------------- -------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
------------------------------------- -------------------- -----------
Number (%) Number (%)
------------------------------------- ---------- -------- ------ ---
(1) Relevant securities 68,686,698 4.65144%
------------------------------------- ---------- -------- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------- ---------- -------- ------ ---
(3) Options and agreements to
purchase/sell N/A
------------------------------------- ---------- -------- ------ ---
Total 68,686,698 4.65144%
------------------------------------- ---------- -------- ------ ---
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
------------------------------------------- ----------- -----------
Number (%) Number (%)
------------------------------------------- ------ --- ------ ---
(1) Relevant securities N/A
------------------------------------------- ------ --- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------------- ------ --- ------ ---
(3) Options and agreements to purchase/sell N/A
------------------------------------------- ------ --- ------ ---
Total N/A
------------------------------------------- ------ --- ------ ---
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
-------------- ----------------------------- -----------------------
Purchase 49,700 74.55
-------------- ----------------------------- -----------------------
Purchase 551 73.37
-------------- ----------------------------- -----------------------
Purchase 4,251 73.37
-------------- ----------------------------- -----------------------
Purchase 12,000 73.37
-------------- ----------------------------- -----------------------
Purchase 46 73.37
-------------- ----------------------------- -----------------------
Purchase 400 73.37
-------------- ----------------------------- -----------------------
Purchase 2,796 73.37
-------------- ----------------------------- -----------------------
Purchase 596 73.37
-------------- ----------------------------- -----------------------
Purchase 71,120 73.37
-------------- ----------------------------- -----------------------
Purchase 928 73.37
-------------- ----------------------------- -----------------------
Purchase 1,152 73.37
-------------- ----------------------------- -----------------------
Purchase 2,688 73.37
-------------- ----------------------------- -----------------------
Purchase 624 73.37
-------------- ----------------------------- -----------------------
Purchase 5,248 73.37
-------------- ----------------------------- -----------------------
Purchase 500 73.37
-------------- ----------------------------- -----------------------
Purchase 353 73.37
-------------- ----------------------------- -----------------------
Purchase 534 73.37
-------------- ----------------------------- -----------------------
Purchase 488 73.37
-------------- ----------------------------- -----------------------
Sale 800 73.42
-------------- ----------------------------- -----------------------
Sale 96 75.13
-------------- ----------------------------- -----------------------
Sale 1,000 73.37
-------------- ----------------------------- -----------------------
Sale 12,810 75.13
-------------- ----------------------------- -----------------------
Sale 12,000 73.37
-------------- ----------------------------- -----------------------
Sale 600 73.37
-------------- ----------------------------- -----------------------
Sale 30,226 73.37
-------------- ----------------------------- -----------------------
Sale 29,820 73.37
-------------- ----------------------------- -----------------------
Sale 464 73.37
-------------- ----------------------------- -----------------------
Sale 600 73.37
-------------- ----------------------------- -----------------------
Sale 25,281 73.37
-------------- ----------------------------- -----------------------
Sale 3,762 73.37
-------------- ----------------------------- -----------------------
Sale 13,203 73.37
-------------- ----------------------------- -----------------------
Sale 400 73.37
-------------- ----------------------------- -----------------------
Sale 344 73.37
-------------- ----------------------------- -----------------------
Sale 970 73.37
-------------- ----------------------------- -----------------------
Sale 534 73.37
-------------- ----------------------------- -----------------------
Sale 267 73.37
-------------- ----------------------------- -----------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
------------- --------------------- ----------------------------- --------------
N/A
------------- --------------------- ----------------------------- --------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money
e.g. call option purchasing securities to which price American, date paid/received
varying etc. the option relates European etc. per unit (Note 5)
(Note 7)
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
N/A
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
----------------- -------------------- ------------------
N/A
----------------- -------------------- ------------------
(d) Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
--------------------- ------- -------------------------
N/A
--------------------- ------- -------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person
relating to the voting rights of any relevant securities
under any option referred to on this form or relating
to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
referred to on this form is referenced. If none, this
should be stated.
-----------------------------------------------------------
N/A
-----------------------------------------------------------
Is a Supplemental Form 8 attached? (Note 9) NO
------------------------------------------------------- -----------------
Date of disclosure 06(th) April 2020
------------------------------------------------------- -----------------
Contact name Lionel Colaco
------------------------------------------------------- -----------------
Telephone number 020 33956098
------------------------------------------------------- -----------------
If a connected EFM, name of offeree/offeror with which N/A
connected
------------------------------------------------------- -----------------
If a connected EFM, state nature of connection (Note N/A
10)
------------------------------------------------------- -----------------
(END) Dow Jones Newswires
April 06, 2020 12:04 ET (16:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Sep 2023 to Sep 2024